Fig. 1From: In vitro characterisation of [177Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancerA Cell binding of [177Lu]Lu-DOTA-C595 at 1 × 105 cells corrected for background and B linear regression of the percentage of positive MUC1-CE cells and average cell binding counts per minuteBack to article page